Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Abstract C050: Leveraging ECM deposition by CAF-like Ewing sarcoma tumor cells to target micrometastases with matrix-binding VHHs

Emma D. Wrenn, Jason P. Price, Raymond O. Ruff, Nicolas M. Garcia, James M. Olson, Elizabeth R. Lawlor

Cancer Res (2024) 84 (22_Supplement): C050.

https://doi.org/10.1158/1538-7445.TUMBODY-C050

Published: 17 November 2024

View articletitled, Abstract C050: Leveraging ECM deposition by CAF-like Ewing sarcoma tumor cells to target micrometastases with matrix-binding VHHs

Journal Articles

Abstract 1043: Advances in cystine-dense peptide (CDP) screening and therapeutic applications

Zachary R. Crook, Emily J. Girard, Gregory P. Sevilla, Mi-Youn Brusniak, Peter B. Rupert, Della J. Friend, Mesfin M. Gewe, Midori Clarke, Ida Lin, Raymond Ruff, Doan Phi, Ashok Bandaranayake, Colin E. Correnti, Andrew J. Mhyre, Natalie W. Nairn, Roland K. Strong, James M. Olson

Cancer Res (2022) 82 (12_Supplement): 1043.

https://doi.org/10.1158/1538-7445.AM2022-1043

Published: 15 June 2022

View articletitled, Abstract 1043: Advances in cystine-dense peptide (CDP) screening and therapeutic applications

Journal Articles

Functional Precision Medicine Identifies New Therapeutic Candidates for Medulloblastoma

Cancer Res (2020) 80 (23): 5393–5407.

https://doi.org/10.1158/0008-5472.CAN-20-1655

Published: 02 December 2020

View articletitled, Functional Precision Medicine Identifies New Therapeutic Candidates for Medulloblastoma

Includes: Supplementary data

Journal Articles

Abstract IA11: Overcoming immune evasion in pediatric brain tumors

Cancer Res (2020) 80 (14_Supplement): IA11.

https://doi.org/10.1158/1538-7445.PEDCA19-IA11

Published: 15 July 2020

View articletitled, Abstract IA11: Overcoming immune evasion in pediatric brain tumors

Journal Articles

Abstract 413: Emerging principles in synthetic lethality in glioblastoma

Pia Hoellerbauer, Sonali Arora, Megan Kufeld, Lucas Carter, Emily J. Girard, Heather Feldman, Philip Corrin, James M. Olson, Patrick J. Paddison

Cancer Res (2018) 78 (13_Supplement): 413.

https://doi.org/10.1158/1538-7445.AM2018-413

Published: 01 July 2018

View articletitled, Abstract 413: Emerging principles in synthetic lethality in glioblastoma

Journal Articles

PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models

Terrence F. Meehan, Nathalie Conte, Theodore Goldstein, Giorgio Inghirami, Mark A. Murakami, Sebastian Brabetz, Zhiping Gu, Jeffrey A. Wiser, Patrick Dunn, Dale A. Begley, Debra M. Krupke, Andrea Bertotti, Alejandra Bruna, Matthew H. Brush, Annette T. Byrne, Carlos Caldas, Amanda L. Christie, Dominic A. Clark, Heidi Dowst, Jonathan R. Dry, James H. Doroshow, Olivier Duchamp, Yvonne A. Evrard, Stephane Ferretti, Kristopher K. Frese, Neal C. Goodwin, Danielle Greenawalt, Melissa A. Haendel, Els Hermans, Peter J. Houghton, Jos Jonkers, Kristel Kemper, Tin O. Khor, Michael T. Lewis, K.C. Kent Lloyd, Jeremy Mason, Enzo Medico, Steven B. Neuhauser, James M. Olson, Daniel S. Peeper, Oscar M. Rueda, Je Kyung Seong, Livio Trusolino, Emilie Vinolo, Robert J. Wechsler-Reya, David M. Weinstock, Alana Welm, S. John Weroha, Frédéric Amant, Stefan M. Pfister, Marcel Kool, Helen Parkinson, Atul J. Butte, Carol J. Bult

Cancer Res (2017) 77 (21): e62–e66.

https://doi.org/10.1158/0008-5472.CAN-17-0582

Published: 01 November 2017

View articletitled, PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models

Includes: Multimedia, Supplementary data

Journal Articles

Abstract 5141: Optimizing peptide-drug conjugate delivery as an alternative to antibody-drug conjugates for solid tumors

Theo L. Sottero, Emily J. Girard, Carrie H. Myers, James M. Olson

Cancer Res (2017) 77 (13_Supplement): 5141.

https://doi.org/10.1158/1538-7445.AM2017-5141

Published: 01 July 2017

View articletitled, Abstract 5141: Optimizing peptide-drug conjugate delivery as an alternative to antibody-drug conjugates for solid tumors

Journal Articles

Abstract 3200: Targeting PHF5A for the treatment of glioblastoma and other Myc-driven cancers

Andrew J. Mhyre, Shanon Turnbaugh, Shelli M. Morris, Hu Xin, Patrick J. Paddison, Marc Ferrer, James M. Olson

Cancer Res (2017) 77 (13_Supplement): 3200.

https://doi.org/10.1158/1538-7445.AM2017-3200

Published: 01 July 2017

View articletitled, Abstract 3200: Targeting PHF5A for the treatment of glioblastoma and other Myc-driven cancers

Journal Articles

Abstract 1935: Molecular characterization of orthotopic patient-derived xenograft models of pediatric brain tumors

Sebastian Brabetz, Susanne N. Gröbner, Huriye Seker-Cin, Florian Selt, Till Milde, David T. Jones, Madison T. Wise, Jessica M. Rusert, Kyle Pedro, Andy Strand, Olaf Witt, Sarah E. Leary, Xiao-Nan Li, Robert J. Wechsler-Reya, James M. Olson, Stefan M. Pfister, Marcel Kool

Cancer Res (2017) 77 (13_Supplement): 1935.

https://doi.org/10.1158/1538-7445.AM2017-1935

Published: 01 July 2017

View articletitled, Abstract 1935: Molecular characterization of orthotopic patient-derived xenograft models of pediatric brain tumors

Journal Articles

Abstract 5573: A high-affinity Optide (optimized peptide) inhibitor of the Hippo pathway’s YAP-TEAD interaction

Zachary R. Crook, Philip Bradley, Gregory Sevilla, Della Friend, Chris King, Andrew Mhyre, Roland Strong, David Baker, James M. Olson

Cancer Res (2017) 77 (13_Supplement): 5573.

https://doi.org/10.1158/1538-7445.AM2017-5573

Published: 01 July 2017

View articletitled, Abstract 5573: A high-affinity Optide (optimized peptide) inhibitor of the Hippo pathway’s YAP-TEAD interaction

Journal Articles

Abstract 4023: The SABRE platform: A novel, unbiased technology for drug discovery and prioritization

Shelli M. Morris, Andrew J. Mhyre, Savanna S. Carmack, Connor Burns, Marc Ferrer, Wenjuan Ye, James M. Olson, Richard A. Klinghoffer

Cancer Res (2017) 77 (13_Supplement): 4023.

https://doi.org/10.1158/1538-7445.AM2017-4023

Published: 01 July 2017

View articletitled, Abstract 4023: The SABRE platform: A novel, unbiased technology for drug discovery and prioritization

Journal Articles

Multidrug Analyses in Patients Distinguish Efficacious Cancer Agents Based on Both Tumor Cell Killing and Immunomodulation

Cancer Res (2017) 77 (11): 2869–2880.

https://doi.org/10.1158/0008-5472.CAN-17-0084

Published: 31 May 2017

View articletitled, Multidrug Analyses in Patients Distinguish Efficacious Cancer Agents Based on Both Tumor Cell Killing and Immunomodulation

Journal Articles

Abstract 2971: Optides (optimized knottin peptides) computationally designed to target the oncogenic HIPPO pathway

Zachary R. Crook, Philip Bradley, Chris King, Andrew J. Mhyre, David Baker, James M. Olson

Cancer Res (2016) 76 (14_Supplement): 2971.

https://doi.org/10.1158/1538-7445.AM2016-2971

Published: 15 July 2016

View articletitled, Abstract 2971: Optides (optimized knottin peptides) computationally designed to target the oncogenic HIPPO pathway

Journal Articles

Preclinical Validation of the Utility of BLZ-100 in Providing Fluorescence Contrast for Imaging Spontaneous Solid Tumors

Janean Fidel, Katie C. Kennedy, William S. Dernell, Stacey Hansen, Valorie Wiss, Mark R. Stroud, Joshua I. Molho, Sue E. Knoblaugh, Jeffrey Meganck, James M. Olson, Brad Rice, Julia Parrish-Novak

Cancer Res (2015) 75 (20): 4283–4291.

https://doi.org/10.1158/0008-5472.CAN-15-0471

Published: 14 October 2015

View articletitled, Preclinical Validation of the Utility of BLZ-100 in Providing Fluorescence Contrast for Imaging Spontaneous Solid Tumors

Includes: Supplementary data

Journal Articles

Abstract 2443: Optides (optimized peptides), a new knottin-based cancer drug discovery platform

James M. Olson, Roland Strong, Christopher Mehlin, Colin Correnti

Cancer Res (2015) 75 (15_Supplement): 2443.

https://doi.org/10.1158/1538-7445.AM2015-2443

Published: 01 August 2015

View articletitled, Abstract 2443: Optides (optimized peptides), a new knottin-based cancer drug discovery platform

Journal Articles

MyoD Is a Tumor Suppressor Gene in Medulloblastoma

Joyoti Dey, Adrian M. Dubuc, Kyle D. Pedro, Derek Thirstrup, Brig Mecham, Paul A. Northcott, Xiaochong Wu, David Shih, Stephen J. Tapscott, Michael LeBlanc, Michael D. Taylor, James M. Olson

Cancer Res (2013) 73 (22): 6828–6837.

https://doi.org/10.1158/0008-5472.CAN-13-0730-T

Published: 14 November 2013

View articletitled, MyoD Is a Tumor Suppressor Gene in Medulloblastoma

Includes: Supplementary data

Journal Articles

Abstract 5055: Efficacy of cabazitaxel in mouse models of pediatric brain tumors.

James M. Olson, Emily Girard, Sally Ditzler, Andrew Richards, Doonhoon Lee, Patricia Vrignaud

Cancer Res (2013) 73 (8_Supplement): 5055.

https://doi.org/10.1158/1538-7445.AM2013-5055

Published: 15 April 2013

View articletitled, Abstract 5055: Efficacy of cabazitaxel in mouse models of pediatric brain tumors.

Journal Articles

Abstract 1431: A novel tumor-suppressor role of MyoD, a muscle differentiation factor, in mouse models of medulloblastoma

Joyoti Dey, Stephen J. Tapscott, James M. Olson

Cancer Res (2012) 72 (8_Supplement): 1431.

https://doi.org/10.1158/1538-7445.AM2012-1431

Published: 15 April 2012

View articletitled, Abstract 1431: A novel tumor-suppressor role of MyoD, a muscle differentiation factor, in mouse models of medulloblastoma

Journal Articles

Abstract 5118: A functional genetic approach in patient-derived glioblastoma stem cells reveals pre-mRNA splicing components to be cancer-lethal gene targets

Christopher G. Hubert, Yu Ding, Chad Toledo, Patrick J. Paddison, James M. Olson, Jason Berndt

Cancer Res (2012) 72 (8_Supplement): 5118.

https://doi.org/10.1158/1538-7445.AM2012-5118

Published: 15 April 2012

View articletitled, Abstract 5118: A functional genetic approach in patient-derived glioblastoma stem cells reveals pre-mRNA splicing components to be cancer-lethal gene targets

Journal Articles

The Smo/Smo Model: Hedgehog-Induced Medulloblastoma with 90% Incidence and Leptomeningeal Spread

Beryl A. Hatton, Elisabeth H. Villavicencio, Karen D. Tsuchiya, Joel I. Pritchard, Sally Ditzler, Barbara Pullar, Stacey Hansen, Sue E. Knoblaugh, Donghoon Lee, Charles G. Eberhart, Andrew R. Hallahan, James M. Olson

Cancer Res (2008) 68 (6): 1768–1776.

https://doi.org/10.1158/0008-5472.CAN-07-5092

Published: 13 March 2008

View articletitled, The Smo/Smo Model: Hedgehog-Induced Medulloblastoma with 90% Incidence and Leptomeningeal Spread

Includes: Supplementary data

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract C050: Leveraging ECM deposition by CAF-like Ewing sarcoma tumor cells to target micrometastases with matrix-binding VHHs

Abstract 1043: Advances in cystine-dense peptide (CDP) screening and therapeutic applications

Functional Precision Medicine Identifies New Therapeutic Candidates for Medulloblastoma

Abstract IA11: Overcoming immune evasion in pediatric brain tumors

Abstract 413: Emerging principles in synthetic lethality in glioblastoma

PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models

Abstract 5141: Optimizing peptide-drug conjugate delivery as an alternative to antibody-drug conjugates for solid tumors

Abstract 3200: Targeting PHF5A for the treatment of glioblastoma and other Myc-driven cancers

Abstract 1935: Molecular characterization of orthotopic patient-derived xenograft models of pediatric brain tumors

Abstract 5573: A high-affinity Optide (optimized peptide) inhibitor of the Hippo pathway’s YAP-TEAD interaction

Abstract 4023: The SABRE platform: A novel, unbiased technology for drug discovery and prioritization

Multidrug Analyses in Patients Distinguish Efficacious Cancer Agents Based on Both Tumor Cell Killing and Immunomodulation

Abstract 2971: Optides (optimized knottin peptides) computationally designed to target the oncogenic HIPPO pathway

Preclinical Validation of the Utility of BLZ-100 in Providing Fluorescence Contrast for Imaging Spontaneous Solid Tumors

Abstract 2443: Optides (optimized peptides), a new knottin-based cancer drug discovery platform

MyoD Is a Tumor Suppressor Gene in Medulloblastoma

Abstract 5055: Efficacy of cabazitaxel in mouse models of pediatric brain tumors.

Abstract 1431: A novel tumor-suppressor role of MyoD, a muscle differentiation factor, in mouse models of medulloblastoma

Abstract 5118: A functional genetic approach in patient-derived glioblastoma stem cells reveals pre-mRNA splicing components to be cancer-lethal gene targets

The Smo/Smo Model: Hedgehog-Induced Medulloblastoma with 90% Incidence and Leptomeningeal Spread

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only